Navigation Links
Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
Date:12/8/2008

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval of agents to treat glioma, most notably Roche/Genentech/Chugai's Avastin, will drive market sales to more than double to more than $1.8 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Glioma finds that sales of Avastin, which is already used off-label to treat relapsed glioma and is in development for treating both relapsed and newly-diagnosed patients, will account for more than half of the total market in 2017. Sales of Schering-Plough's Temodar/Temodal, the current leading agent for glioma in both patient share and market share, will fall significantly from 2007 to 2017, owing to generic erosion.

According to the report, in addition to Avastin, the launches of Celldex Therapeutics/Pfizer's CDX-110 and Merck KGaA's cilengitide will also drive market growth. CDX-110 and cilengitide are being developed for use in newly diagnosed glioma patients and would each be used in combination with Temodar/Temodal. Additionally, overall sales for glioma therapies will be fueled by the launch of AstraZeneca's Recentin, which is in development for relapsed treatment.

"The treatment of glioma, especially the most malignant form--glioblastoma multiforme--is largely ineffective, and the prognosis for these patients is very poor," said Ramya Kollipara, Ph.D. analyst at Decision Resources. "Considerable opportunity remains in this market as currently-approved agents provide only modest improvements in patient outcomes, leaving a high level of unmet need."

About
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA Panel Says No to Avastin for Advanced Breast Cancer
2. Taxol with avastin produces noteworthy results
3. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. FDA OKs Avastin for Advanced Breast Cancer
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
10. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
11. Another Reason Not to Smoke While Pregnant: Birth Defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... of Catholics for Choice, issued the following statement on Respect ... Catholic Bishops holds its annual Respect Life Sunday. On this ... also respect the truth. A recent publication by the USCCB, ... on healthcare reform prove that the bishops, desire to promote ...
... , WILMINGTON, Del., Oct. 2 Nationwide Health ... of 4,000 production transactions processed through the NHIN ... CONNECT solution. , CONNECTfx was developed ... NHIEs, HIEs, and other collaborative healthcare organizations by ...
... NASHVILLE, Tenn., Oct. 2 Brookdale Senior Living Inc. (NYSE: ... Chief Financial Officer, will make a presentation regarding the Company ... New York on Monday, October 5, 2009, beginning at 3:30 ... live and can be accessed on the Internet at ...
... risk rises when transfused blood is more than 28 days old, ... suffered severe trauma and are given a major transfusion of red ... are twice as likely to die as those who receive fresher ... of 202 severe trauma patients who were treated with five or ...
... Oct. 2 Brent Phillips, a senior executive at ... officer of Aurora Medical Group. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ... the 960-physician medical group. , "Brent will ... Jeff Bailet, M.D., president of Aurora Medical Group. ...
... a long way in the last decade. Today, one can talk, ... even access the Web. Now imagine a cell phone that can ... test water quality after a major disaster like a hurricane or ... engineering at UCLA,s Henry Samueli School of Engineering and Applied Science, ...
Cached Medicine News:Health News:Respect Life and the Truth on Respect Life Sunday 2Health News:Respect Life and the Truth on Respect Life Sunday 3Health News:NHIT Processes Over 4,000 Production Transactions, Advances Adoption of NHIN Initiative 2Health News:Fresh Blood Boosts Survival in Trauma Patients 2Health News:Mayo Clinic Executive Brent Phillips to Join Aurora Medical Group as Chief Operating Officer 2Health News:NIH recognizes engineering professor's innovative research with major award 2Health News:NIH recognizes engineering professor's innovative research with major award 3
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Intermittent catheter...
Medicine Products: